Basic Cipralex Information

• INN (International Nonproprietary Name): Escitalopram.
• Brand Names Available In United Kingdom: Lexapro (widely used in USA, Canada and UK) and generic escitalopram formulations are commonly available.
• ATC Code: N06AB10.
• Forms & Dosages: Film-coated tablets in 5 mg, 10 mg, 15 mg and 20 mg strengths are listed in various markets.
• Oral Solution: Oral solutions are manufactured in strengths including 1 mg/mL and 10 mg/mL depending on country.
• Manufacturers In United Kingdom: Lundbeck is the original developer and global supplier, with multiple generics supplied by companies such as Teva and Sandoz in the UK market.
• Registration Status In United Kingdom: Licensed formulations include Lexapro and generic escitalopram; escitalopram is approved in major jurisdictions and is included on the WHO List of Essential Medicines.
• OTC / Rx Classification: Prescription only (Rx) in all major jurisdictions.

Key Findings From Recent Trials

Major 2022–2025 Studies

Which trials have changed how clinicians choose treatment?

Large randomised trials and network meta-analyses published between 2022 and mid-2024 repeatedly evaluated escitalopram against other SSRIs and newer comparators.

Those studies examined adult patients with major depressive disorder and generalised anxiety disorder across multiple settings and compared standard adult doses of escitalopram (10–20 mg) to drugs like sertraline and paroxetine.

The collective evidence reinforced escitalopram’s role as a first-line SSRI for depression and anxiety in many analyses.

Findings reflected in NHS audit data show escitalopram (Lexapro/Cipralex or generic escitalopram) is commonly prescribed in the UK.

Main Outcomes

How quickly and how well does escitalopram work?

Trials showed effect sizes for escitalopram comparable to sertraline for symptom reduction in depression and anxiety scales.

Some pooled analyses reported faster symptomatic improvement on anxiety measures with escitalopram compared with older SSRIs.

Head-to-head trials often measured response and remission at 6–8 weeks and found escitalopram had higher response/remission rates versus some older agents at standard dosing.

Meta-analyses generally reported lower dropout rates due to adverse events for escitalopram versus several comparators, supporting a favourable tolerability profile in real-world practice.

Safety Observations

What safety signals should prescribers watch?

Adverse-event patterns in the trials matched known SSRI class effects: sexual dysfunction, gastrointestinal upset and discontinuation symptoms with abrupt stopping.

Cohort analyses highlighted cardiac safety monitoring for QT prolongation risk, especially with supratherapeutic dosing or when patients had pre-existing QT risk factors.

Serotonin syndrome and hyponatraemia were flagged as recognised but uncommon risks, particularly in elderly or polymedicated patients.

Overall, safety reporting supports escitalopram’s tolerability advantage over paroxetine in several analyses, consistent with lower discontinuation rates.

Clinical Mechanism Of Action

Layman’s Explanation

How does escitalopram make people feel better?

Escitalopram is a selective serotonin reuptake inhibitor that increases the amount of serotonin available between nerve cells, which helps mood and anxiety symptoms over time.

Put simply, it stops nerve cells from taking serotonin back too quickly so signals that lift mood and reduce anxiety can work more effectively.

Patients often notice gradual improvement rather than an immediate mood lift.

Scientific Breakdown

What is the pharmacology behind that effect?

Escitalopram is the S‑enantiomer of citalopram and binds with high affinity to the serotonin transporter (SERT), producing potent and selective SERT inhibition at therapeutic plasma concentrations.

Typical adult doses are 10–20 mg daily and steady state is usually achieved in about one week of dosing.

Metabolism occurs in the liver largely via CYP2C19, CYP3A4 and CYP2D6, so there are modest interaction risks with inhibitors or in poor metabolisers.

Increased S‑enantiomer selectivity compared with racemic citalopram explains greater potency per milligram and contributes to the observed tolerability differences in trials.

Clinical effects also involve downstream neuroplastic changes that develop over several weeks of continued therapy.

Contraindications of note include coadministration with monoamine oxidase inhibitors and linezolid, and dose reductions are recommended for hepatic impairment and frail older adults.

Scope Of Approved And Off-Label Use

United Kingdom Approvals

What is escitalopram licensed for in the UK?

Escitalopram is authorised as a treatment for major depressive disorder and generalised anxiety disorder and is available as Lexapro or generic escitalopram in UK practice.

Regulatory approvals include US FDA since 2002 and EMA/national agencies in Europe, and the drug is listed by WHO as an essential medicine.

NICE and MHRA guidance support SSRIs, including escitalopram, for moderate-to-severe depression and for GAD as first- or second-line options within stepped-care pathways.

Notable Off-Label Trends

When do clinicians use escitalopram beyond the label?

Off-label use is observed for adjunctive management of chronic neuropathic pain and for social anxiety disorder when alternatives are poorly tolerated.

Specialist paediatric psychiatry sometimes uses escitalopram in adolescents from age 12 for major depressive disorder where licensed locally.

Some clinicians use escitalopram off-label in difficult-to-treat anxiety spectrum conditions with careful monitoring and adherence to local guidelines.

Prescribers must follow contraindications, titration rules and NICE stepped-care guidance when considering off-label use.

Dosage Strategy

General Dosing

What dose should a typical adult start on?

Standard adult dosing begins at 10 mg once daily for both major depressive disorder and generalised anxiety disorder.

Up-titration to 20 mg daily is an option for inadequate response, with 20 mg as the labelled maximum for adults.

Tablets are available in 5 mg, 10 mg, 15 mg and 20 mg strengths and oral solutions include 1 mg/mL and 10 mg/mL where supplied.

Elderly patients and those with hepatic impairment should generally start and remain at 10 mg daily because of increased sensitivity.

Missed-dose instructions are to take the dose as soon as remembered unless close to the next dose and not to double up.

Condition-Specific Dosing

Are dosing rules different for specific groups?

Adolescents aged 12 and over may be prescribed 10 mg daily for major depressive disorder where local approvals permit that use.

For OCD, some countries have approvals at higher doses and different titration schedules; UK clinicians follow local specialist advice for those indications.

Treatment duration typically requires a minimum eight-week acute phase with maintenance for several months to reduce relapse risk.

Discontinuation should be by gradual dose reduction to reduce the risk of discontinuation syndrome symptoms such as dizziness and sensory disturbances.

Safety Protocols

Contraindications

Who should not take escitalopram?

Absolute contraindications include hypersensitivity to escitalopram, concurrent use of MAO inhibitors including linezolid and methylene blue, recent pimozide use and known long QT syndrome.

Relative cautions apply in patients with a history of bipolar disorder, seizure disorders, bleeding tendencies and severe renal impairment.

Clinicians should review the full SmPC and consider baseline cardiac risk when multiple QT‑prolonging agents are present.

Adverse Effects

What side effects should patients expect and how common are they?

Common mild-to-moderate adverse effects include headache, nausea, somnolence or insomnia, fatigue, dry mouth, increased sweating, sexual dysfunction and dizziness.

Serious but less frequent risks include serotonin syndrome when combined with other serotonergic agents, hyponatraemia especially in the elderly, and QT prolongation in at-risk patients.

Monitoring recommendations in the UK include a medication review for interacting QT agents, caution with anticoagulants and antiplatelets because of bleeding risk, and gradual tapering on discontinuation.

Interaction Mapping

Food Interactions

Does food affect escitalopram?

There are no major food-intake restrictions specific to escitalopram, but alcohol should be discouraged because it can worsen sedation and depressive symptoms.

Patients should be counselled about alcohol avoidance while initiating treatment and during dose changes.

Drug Combinations To Avoid

Which drugs must be avoided or monitored closely?

Concomitant use of MAO inhibitors, including linezolid and methylene blue, is an absolute contraindication due to the risk of serotonin syndrome.

Pimozide coadministration is contraindicated.

Other serotonergic drugs such as triptans, tramadol, SNRIs and lithium increase serotonin syndrome risk and require close supervision or alternative choices.

Escitalopram is metabolised in part by CYP2C19, CYP3A4 and CYP2D6, so strong inhibitors or poor metaboliser status can raise exposure and may need dose adjustment.

Coadministration with QT-prolonging drugs such as certain antipsychotics or antiarrhythmics should be avoided or accompanied by ECG monitoring.

Antiplatelet agents and anticoagulants raise bleeding risk when combined with SSRIs and require monitoring according to BNF and MHRA guidance.

Patient Experience Analysis

Survey Data

What do patient surveys tell us about escitalopram?

NHS patient-reported outcome measures and quantitative surveys commonly rate escitalopram positively for symptom relief and tolerability compared with older SSRIs.

Many patients report some improvement within 2–4 weeks, with clearer benefit by 6–8 weeks.

Common complaints noted in surveys are early nausea, transient sleep disturbance and sexual dysfunction, which sometimes prompt switching.

Forum Trends

What are patients saying on peer forums?

Online patient forums and peer-support groups show variability in experience: some users report fast benefit at 10 mg with minimal side effects, while others report persistent libido issues or troublesome discontinuation symptoms if stopped abruptly.

Withdrawal accounts such as dizziness and “brain zaps” reinforce clinician advice on gradual tapering.

Cost-conscious patients in the UK often prefer generic escitalopram, while brand names such as Cipralex and Lexapro are mentioned in discussions about perceived reliability.

Distribution And Pricing Landscape

Where and how is escitalopram supplied in the UK?

Escitalopram is widely available in the UK as Lexapro and multiple generics supplied by major manufacturers including Lundbeck, Teva and Sandoz.

Pharmacies typically stock film-coated tablets in 5 mg, 10 mg and 20 mg strengths and, where available, oral solution formulations for dose flexibility.

NHS prescribing favours cost-effective generics and tendering keeps the cost per item low for routine prescriptions.

Private prescriptions and online pharmacies may supply brand or generic products according to patient preference and prescription verification.

As a note on access, in our online pharmacy cipralex is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Illicit online purchases are discouraged and patients should always use registered pharmacies that verify prescriptions.

Alternative Options

Comparison Snapshot

How does escitalopram compare with other SSRIs and SNRIs?

Escitalopram and sertraline have similar efficacy for depression and anxiety, with escitalopram often preferred by some patients for tolerability and in some analyses for faster anxiety relief.

Fluoxetine has a longer half-life which can reduce discontinuation effects but may be more activating.

Paroxetine is effective but has higher rates of sexual side effects and weight gain.

Citalopram is the racemic parent compound and is less potent per milligram than escitalopram.

SNRIs such as venlafaxine and duloxetine may offer benefits for neuropathic pain and certain depressive presentations but carry their own withdrawal and cardiovascular considerations.

Pros And Cons

What are the main advantages and limitations of escitalopram?

Pros include potency, flexible dosing options (5–20 mg), a well-studied tolerability profile and often lower dropout rates in trials.

Cons include sexual dysfunction, potential QT concerns at higher doses or in at-risk patients, and interactions with multiple drugs.

Choice of agent should be individualised based on comorbidity, interaction potential, pregnancy planning and patient preference, following NICE pathways.

Regulatory Status

Approvals & Listings

Where is escitalopram approved and how is it classified?

Escitalopram is approved by major regulatory agencies including the US FDA (since 2002), EMA and national agencies such as MHRA in the UK.

The drug is included on the WHO List of Essential Medicines and is registered in many countries under brands such as Lexapro and Cipralex and various generics.

Classification across jurisdictions is prescription-only (Rx).

Pharmacovigilance Notes

How is escitalopram monitored post-marketing?

Escitalopram is subject to routine adverse-event reporting and regulatory surveillance by agencies such as MHRA and EMA.

Safety communications have focused on QT prolongation, hyponatraemia and serotonin syndrome among other recognised risks.

Clinicians are advised to consult up-to-date SmPC documents and national safety updates for country-specific guidance before prescribing.

Consolidated FAQ

Quick Answers For Clinicians And Patients

Can patients start at 20 mg?

Start at 10 mg for adults and consider 20 mg only if response is inadequate, noting the maximum adult dose is 20 mg.

Is escitalopram safe in older adults?

Use 10 mg as the initial and typically maximum dose for frail or elderly patients and for those with hepatic impairment.

How long until patients see an effect?

Some improvement may appear within 2–4 weeks, with assessment of efficacy at 6–8 weeks.

Can it be taken with warfarin or NSAIDs?

Co-prescription increases bleeding risk and merits careful monitoring.

Is alcohol allowed?

Alcohol is discouraged as it may worsen sedation and depressive symptoms.

What about pregnancy?

Prescribing during pregnancy requires a risk–benefit discussion and specialist input where appropriate.

Common Misconceptions

Do SSRIs act immediately?

No; SSRIs typically take weeks for full clinical effect and patients should be counselled accordingly.

Are generics inferior?

No; NHS practice supports generics as therapeutically equivalent to branded formulations such as Cipralex and Lexapro.

Visual Guide

Suggested Schematic Elements

Which visuals help clinicians and patients quickly understand escitalopram?

A mechanism diagram showing SERT blockade and increased synaptic serotonin helps explain action to patients.

A dosing flowchart is useful: start 10 mg → review 2–4 weeks → consider escalation to 20 mg if needed → maintenance → taper.

A risk checklist infographic that highlights QT risk, MAOI contraindication, bleeding risk and pregnancy caution is practical for clinics.

Packaging images of film-coated tablets (5/10/20 mg) and oral solution labels support accurate dispensing and patient identification.

Clinical Quick-Reference Infographic

What should be on a one-page quick reference?

Include licence indications (MDD, GAD), starting doses, elderly/hepatic adjustment (10 mg), common side effects and discontinuation instructions.

Use UK-specific icons for NHS prescribing and MHRA/SmPC resources and ensure accessibility with colour-blind friendly palettes.

Storage And Transport

Pharmacy Best Practice

How should pharmacies store escitalopram stock?

Store below 25°C in a dry place and keep the product in its original packaging to protect from moisture.

Follow UK Good Distribution Practice for prescription medicines and maintain secure stock control and expiry checks.

For oral solutions, follow manufacturer guidance on storage conditions and expiry after opening where specified.

Home Storage Advice

How should patients keep their medication at home?

Advise patients to keep tablets in their original packaging, out of reach of children and away from high heat or damp.

Recommend returning expired or unused medicines to the pharmacy for safe disposal.

Guidelines For Proper Use

Prescribing Checklist

What should prescribers confirm before issuing a script?

Confirm diagnosis per NICE pathways and review current medicines for MAOIs, QT-prolonging drugs and anticoagulants.

Assess cardiac history for long QT, consider baseline liver tests if indicated and discuss pregnancy and breastfeeding plans.

Provide patient education on expected timelines, side effects, alcohol avoidance and the need for gradual tapering on discontinuation.

Follow-Up And Tapering

What monitoring schedule should be used?

Review patients at 2–4 weeks for tolerability and at 6–8 weeks for efficacy, with routine maintenance reviews every three months or as clinically required.

Tapering should be individualised and gradual, with a slower reduction after long-term use to mitigate discontinuation symptoms.

Document shared decision-making and supply the patient with the SmPC or a patient leaflet as part of counselling.

Delivery Across United Kingdom